Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Seung Woon | - |
dc.contributor.author | Um, Soon Ho | - |
dc.contributor.author | Lee, Han Ah | - |
dc.contributor.author | Kim, Sang Hyun | - |
dc.contributor.author | Sim, Yura | - |
dc.contributor.author | Yim, Sun Young | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Ryu, Ho Sang | - |
dc.date.accessioned | 2021-09-03T23:10:50Z | - |
dc.date.available | 2021-09-03T23:10:50Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2016-06 | - |
dc.identifier.issn | 2287-2728 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/88410 | - |
dc.description.abstract | Autoimmune hepatitis (AIH) is an immune-mediated chronic liver disease characterized by hepatocellular inflammation, necrosis, and fibrosis, which can progress to cirrhosis and fulminant hepatic failure. The standard treatment for AIH includes corticosteroids alone or in combination with azathioprine. Although most patients achieve remission using the standard regimen, some patients do not respond due to either drug intolerance or refractory disease; in such cases alternative immunosuppressive agents should be explored. The second-line therapies are cyclophilin inhibitors such as cyclosporine A or tacrolimus, and nowadays mycophenolate mofetil (MMF) is widely used if azathioprinebased therapies are not tolerated. Although these are recommended as an alternative to the first-line regimen, there is insufficient evidence for the efficacy of second-line therapies, with the evidence based mainly on expert opinion. Therefore, we report an AIH patient receiving the standard regimen in whom remission did not occur due to side effects to azathioprine, but was successfully treated with MMF in combination with corticosteroids as an alternative to the standard regimen. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ASSOC STUDY LIVER | - |
dc.subject | ACTIVE CHRONIC HEPATITIS | - |
dc.subject | THIOPURINE METHYLTRANSFERASE | - |
dc.subject | THERAPY | - |
dc.subject | PHARMACOGENETICS | - |
dc.subject | MANAGEMENT | - |
dc.subject | SAFETY | - |
dc.title | Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Um, Soon Ho | - |
dc.identifier.doi | 10.3350/cmh.2015.0040 | - |
dc.identifier.scopusid | 2-s2.0-85050577556 | - |
dc.identifier.wosid | 000407831500011 | - |
dc.identifier.bibliographicCitation | CLINICAL AND MOLECULAR HEPATOLOGY, v.22, no.2, pp.281 - 285 | - |
dc.relation.isPartOf | CLINICAL AND MOLECULAR HEPATOLOGY | - |
dc.citation.title | CLINICAL AND MOLECULAR HEPATOLOGY | - |
dc.citation.volume | 22 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 281 | - |
dc.citation.endPage | 285 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002121472 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | ACTIVE CHRONIC HEPATITIS | - |
dc.subject.keywordPlus | THIOPURINE METHYLTRANSFERASE | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | PHARMACOGENETICS | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordAuthor | Mycophenolate mofetil | - |
dc.subject.keywordAuthor | Autoimmune hepatitis | - |
dc.subject.keywordAuthor | Azathioprine | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.